Cargando…
Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design
BACKGROUND: Platelet-activating factor (PAF) is produced by most inflammatory cells and it is involved in inflammatory and allergic reactions. We aimed to assess the anti-PAF effects of rupatadine and levocetirizine in the upper airways. FINDINGS: Healthy volunteers (HV, N = 10) and seasonal allergi...
Autores principales: | Muñoz-Cano, Rosa, Valero, Antonio, Izquierdo, Ignacio, Sánchez-López, Jaume, Doménech, Alejandro, Bartra, Joan, Mullol, Joaquim, Picado, Cesar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029526/ https://www.ncbi.nlm.nih.gov/pubmed/24499312 http://dx.doi.org/10.1186/1710-1492-9-43 |
Ejemplares similares
-
Platelet activating factor-induced mast cell degranulation is inhibited by rupatadine, and to a lower extent by levocetirizine and desoratadine, in a mast cell line (LAD-2)
por: Mullol, Joaquim, et al.
Publicado: (2013) -
Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020) -
Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine
por: Mullol, Joaquim, et al.
Publicado: (2005) -
Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis
por: Mullol, Joaquim, et al.
Publicado: (2019) -
Chronic rhinosinusitis with nasal polyps and allergic rhinitis as different multimorbid treatable traits in asthma
por: Castillo, José Antonio, et al.
Publicado: (2023)